Functional inhibition of chemokine receptor CCR2 by dicer-substrate-siRNA prevents pain development

Conclusion
Altogether, these results validate CCR2 as a an appropriate molecular target for pain control and demonstrate that RNAi-based gene therapy represent an highly specific alternative to classical pharmacological approaches to treat central pathologies such as chronic pain.

Source: Molecular Pain - June 14, 2016 Category: Molecular Biology Authors: Begin-Lavallee, V., Midavaine, E., Dansereau, M.-A., Tetreault, P., Longpre, J.-M., Jacobi, A. M., Rose, S. D., Behlke, M. A., Beaudet, N., Sarret, P. Tags: Research Article Source Type: research